<DOC>
	<DOCNO>NCT00141830</DOCNO>
	<brief_summary>The primary objective study compare efficacy safety 3 dose level oral ERB-041 administer daily 12 week versus placebo subject active rheumatoid arthritis suboptimal response therapy stable dos methotrexate ( MTX ) .</brief_summary>
	<brief_title>Study Evaluating ERB-041 With Methotrexate Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Clinical diagnosis active rheumatoid arthritis least 6 month stable dose methotrexate least 12 week Rheumatoid arthritis onset 16 year age Any significant health problem rheumatoid arthritis History male female reproductive system cancer Clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>